Stethophone™ Receives Full Approval for Use by Patients and Their Families in Ukraine

Ukraine clears breakthrough SaaMD that enables people to usetheir smartphones as clinical-grade devices that listen for cardiovascular disease at home

Sparrow BioAcoustics today announced it has received clearance from the State Service of Ukraine for Medicines and Drugs Control for its Stethophone™ app to be used by patients and their families, as well as by medical professioinals.

“Sparrow BioAcoustics is proud to receive its first full approval for patients to use Stethophone in Ukraine,” said Mark Opauszky, CEO of Sparrow. “Like many people, members of our team are close to Ukraine and neighboring countries in Eastern Europe. We wanted to be able to help patients in this nation. Like the U.S. Food and Drug Administration, the Ukrainian health authority is known for its high standards and strong focus on public safety.”

Earlier this year, the FDA granted clearance for Stethophone to be used by medical professionals and emergency medical technicians to monitor, record and share the sounds of the heart and lungs. In Sparrow’s clinical tests, Stethophone outperforms the class-leading traditional stethoscopes in cardiac and pulmonary auscultation.

Stethophone is a breakthrough Software as a Medical Device (SaaMD) app that enables smartphones to capture, isolate and evaluate the sounds of the heart and lungs simply by placing the microphone of a smartphone against a patient’s chest. The information is processed for both visual and auditory evaluation, and can be securely shared with other members of the care team. This makes Stethophone the clinical-grade stethoscope that is always with you, and can capture the sounds of symptoms whenever and wherever they occur.

The downloadable Stethophone™ application uses advanced acoustic processing to provide smartphones with highly sensitive cardiac and pulmonary listening capability. Stethophone is unique in that there is nothing new to plug in, charge, or connect. Heart and lung sounds are captured by simply holding a smartphone to a patient’s chest.

“There is a world of diagnostic information contained in chest sounds, and the healthcare system needs a practical way to capture this data and put it to work for the benefit of patients,” said Opauszky. “Stethophone is the tool to do this.”

In trials conducted at Eastern Health Medical Centre, Newfoundland, Canada, 70 percent of medical professionals rated Stethophone superior in diagnostic sound performance over other leading devices. Stethophone also performed significantly higher in overall correct heart pathology diagnosis and correct normal heart diagnosis.

Cardiovascular diseases (CVDs) are the leading cause of death globally, representing 32 percent of all global deaths. The number of people at risk of CVD is on the rise. The American heart association reports that nearly half of all U.S. adults have some type of cardiovascular disease.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.
“These study results are highly encouraging especially given the short treatment duration of 10 days with BX004,” said Jonathan Solomon, Chief Executive Officer of BiomX. “In Part 2 of the study, BX004 showed clinically meaningful improvement in pulmonary function compared to placebo, as measured by relative FEV11 improvement (5.67% at Day 17, 1 week after end of treatment) and Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain (8.87 points at Day 17) in a predefined subgroup of patients with reduced lung function.”  
Importantly, the study reported no serious treatment-related adverse events from any of the 109 patients treated with InGeneron’s Transpose® RT cell therapy system.

By using this website you agree to accept Medical Device News Magazine Privacy Policy